Department of Urology, Mayo Clinic, Rochester, MN, USA.
Urology. 2013 Jul;82(1):136-41. doi: 10.1016/j.urology.2013.02.034. Epub 2013 May 1.
To evaluate the impact of tumor histology on clinicopathologic outcomes for patients with renal cell carcinoma (RCC) and venous tumor thrombus (VTT).
We identified 807 patients with RCC and VTT who underwent nephrectomy at our institution between 1970 and 2008. All pathologic specimens were re-reviewed by a single urologic pathologist. Patients with non-clear cell RCC (non-ccRCC, n = 56) were matched 1:2 to patients with clear cell RCC (ccRCC) VTT based on symptoms at presentation, regional lymph node involvement, distant metastases, tumor thrombus level, nuclear grade, and sarcomatoid differentiation. Survival was estimated using the Kaplan-Meier method and compared with the log-rank test.
The 56 patients with non-ccRCC VTT included 26 papillary, 11 chromophobe, 5 collecting duct tumors, and 14 RCCs not otherwise specified. Compared to unmatched patients with ccRCC VTT (n = 751), patients with non-ccRCC VTT presented with larger tumor size (P = .02), higher nuclear grade (P = .04), and more frequent sarcomatoid differentiation (P <.001) and lymph node invasion (P <.001). However, when patients with non-ccRCC were matched to patients with ccRCC, no significant differences were noted with regard to 5-year metastases-free survival (41% vs 34%, P = .24) or cancer-specific survival (25% vs 27%, P = .97).
Non-ccRCC VTT is associated with a high rate of adverse pathologic features. Nevertheless, when matched to patients with ccRCC, patients with non-ccRCC VTT did not have increased rate of recurrence or adverse survival. Aggressive surgical resection represents the mainstay of treatment in these cases, whereas continued efforts to optimize a multimodal management approach to such patients remain necessary.
评估肿瘤组织学对肾细胞癌(RCC)伴静脉肿瘤血栓(VTT)患者临床病理结局的影响。
我们在我院回顾性分析了 1970 年至 2008 年间 807 例接受肾切除术的 RCC 伴 VTT 患者。所有病理标本均由一名泌尿科病理学家重新审查。根据患者就诊时的症状、区域淋巴结受累、远处转移、肿瘤血栓水平、核分级和肉瘤样分化,将非透明细胞肾细胞癌(非 ccRCC)患者(n=56)与透明细胞肾细胞癌(ccRCC)VTT 患者进行 1:2 配对。采用 Kaplan-Meier 法估计生存情况,并采用对数秩检验比较。
56 例非 ccRCC VTT 患者包括 26 例乳头状癌、11 例嫌色细胞癌、5 例集合管肿瘤和 14 例未分类 RCC。与未配对的 ccRCC VTT 患者(n=751)相比,非 ccRCC VTT 患者的肿瘤体积更大(P=0.02)、核分级更高(P=0.04)、肉瘤样分化和淋巴结侵犯更常见(均 P<0.001)。然而,当非 ccRCC 患者与 ccRCC 患者相匹配时,两组患者 5 年无转移生存率(41% vs 34%,P=0.24)和癌症特异性生存率(25% vs 27%,P=0.97)无显著差异。
非 ccRCC VTT 与不良病理特征的发生率较高有关。然而,与 ccRCC 患者相匹配时,非 ccRCC VTT 患者的复发率和生存情况并未增加。积极的手术切除是这些患者的主要治疗方法,而对于这些患者,仍需要继续努力优化多模式治疗方法。